Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Cobimetinib
Tyrosine Kinase Inhibitor · Antineoplastic
Tyrosine Kinase InhibitorAntineoplastic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Manufacturer advises avoid unless essential - toxicity in animal studies.
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- Aminolevulinic AcidSevereDatabaseDDInter
- AmprenavirSevereDatabaseDDInter
- ApalutamideSevereDatabaseDDInter
Mechanism
Cobimetinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and kinase 2 (MEK2), which are part of the mitogen-activated protein kinase (MAPK) signaling pathway. In patients with BRAF V600E or V600K mutation-positive metastatic melanoma, its use in combination with a BRAF inhibitor disrupts downstream signaling pathways involved in cell growth and proliferation.
Indications
Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma (in combination with a BRAF inhibitor)unresectable or metastatic melanoma with a BRAF V600E/K mutation (in combination with vemurafenib)combination with BRAF inhibitors for melanomas that harbor a mutation at position 600 in BRAF
Dosing
- Adult
- 60 mg once daily for 21 days; subsequent cycles repeated after a 7-day interval
Pharmacokinetics
Half-life
1 to 3 days
Metabolism
CYP3A (substrate)
Side effects
Common
Anaemiabasal cell carcinomachillsdehydrationdiarrhoeaelectrolyte imbalancefeverhaemorrhagehyperglycaemiahypertensionnauseaphotosensitivity reactionpneumonitisserous retinopathyskin reactionsvision disordersvomitingdiarrheapyrexiaheadachearthralgias
Serious
- Rhabdomyolysis
- major hemorrhagic events
- cardiomyopathy
- cardiac toxicities
- ocular toxicities
Pregnancy & lactation
Pregnancy
Manufacturer advises avoid unless essential - toxicity in animal studies.
Lactation
Manufacturer advises avoid - no information available.
Drug interactions
Aminolevulinic Acid
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Aprepitant
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Berotralstat
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Boceprevir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Bosentan
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Cenobamate
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Related guidelines
Heart failure in diabetes
RSSDI · Cardiology · 2023
Beta-blockers in hypertension
MOHFW · Cardiology · 2024
GI bleeding on antiplatelet or anticoagulant therapy
CSI · Cardiology · 2020
ST-elevation myocardial infarction
CSI · Cardiology · 2020
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Other Tyrosine Kinase Inhibitor drugs
Ask House about Cobimetinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, Katzung, BNF·Verified: 2026-05-10 · House clinical team